Ryanodine receptor and immune-related molecules in diabetic cardiomyopathy

Cheng-Ju Tian¹, Jing-Hua Zhang², Jinfeng Liu³, Zhuang Ma¹* and Zhong Zhen³*

¹College of Rehabilitation and Sports Medicine, Jinzhou Medical University, Jinzhou, China; ²Department of Psychiatry, Tianjin Anding Hospital, Tianjin, China; and ³Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Abstract

Hyperglycaemia is a major aetiological factor in the development of diabetic cardiomyopathy. Excessive hyperglycaemia increases the levels of reactive carbonyl species (RCS), reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the heart and causes derangements in calcium homeostasis, inflammation and immune-system disorders. Ryanodine receptor 2 (RyR2) plays a key role in excitation–contraction coupling during heart contractions, including rhythmic contraction and relaxation of the heart. Cardiac inflammation has been indicated in part through interleukin 1 (IL-1) signals, supporting a role for B and T lymphocytes in diabetic cardiomyopathy. Some of the post-translational modifications of the ryanodine receptor (RyR) by RCS, ROS and RNS stress are known to affect its gating and Ca²⁺ sensitivity, which contributes to RyR dysregulation in diabetic cardiomyopathy. RyRs and immune-related molecules are important signalling species in many physiological and pathophysiological processes in various heart and cardiovascular diseases. However, little is known regarding the mechanistic relationship between RyRs and immune-related molecules in diabetes, as well as the mechanisms mediating complex communication among cardiomyocytes, fibroblasts and immune cells. This review highlights new findings on the complex cellular communications in the pathogenesis and progression of diabetic cardiomyopathy. We discuss potential therapeutic applications targeting RyRs and immune-related molecules in diabetic complications.

Keywords Ryanodine receptors; Immune-related molecules; Fibroblasts; Immune cells; Cardiomyocytes

Introduction

Diabetic cardiomyopathy (DCM) is defined as the existence of abnormal myocardial structure and performance in the absence of other cardiac risk factors, such as dilated cardiomyopathy and congestive heart failure, in individuals with diabetes mellitus.¹–³ Excessive hyperglycaemia leads to an imbalance between oxidative and antioxidative processes within cells and tissues, which leads to an increase in reactive carbonyl species (RCS), reactive oxygen species (ROS) and advanced glycation end products (AGEs).⁴–⁶ A substantial amount of data has demonstrated that ryanodine receptor 2 (RyR2) plays a key role in heart contractions, including rhythmic contraction and relaxation of the heart. Ryanodine receptor 1 (RyR1) is also expressed at low levels in smooth muscle cells, affecting vessel constriction, which, in turn, affects heart function.⁷–¹⁰ Protein carbonylation represents the most common type of non-enzymatic post-translational modification (PTM) in a rat model of Type 1 diabetes. PTMs by RCS, AGEs and ROS contribute to the heterogeneity in RyR2 activity that is observed in experimental models of diabetes.¹¹,¹² These findings have identified PTMs of RyR1 and RyR2 as a novel mechanism that contributes to RyR dysregulation in DCM.

Inflammation increases the risk of ischaemic and non-ischaemic cardiomyopathy. Both innate and adaptive immune responses are activated in the heart in response to inflammation-related tissue injury that results from the pathogenesis of DCM. Additionally, activation of immune responses in the heart provokes deleterious cardiac remodeling and causes left ventricular dysfunction.¹³,¹⁴ A better understanding of the relationship of the pathophysiological
mechanisms between immune responses and dysfunction of RyR1/RyR2 in DCM may lead to medical progress and therapy for those with chronic DCM. We provide an updated discussion on the pathophysiological relationship between immune-related molecules and RyR1/RyR2, which involves cross-talk among myocytes, fibroblasts and immune cells, leading to different pathological processes relevant to the cardiovascular complications of DCM.

Immune dysfunction in diabetes mellitus

Diabetic patients show an altered number and function of immune cells, in terms of both innate and acquired immunity. Over the past few decades, it has been suggested that immune responses play an important role in the mechanisms of diabetes mellitus. Innate immune responses represent the first line of defence against non-self pathogens. Interleukin 1 (IL-1) (IL-1α and IL-1β) stimulates insulin secretion and biosynthesis, as well as β-cell proliferation.15,16 These findings indicate an important physiological role of innate immune signalling in priming insulin secretion under conditions of stress and increased insulin demand.17 Diabetes is generally long-lasting and difficult to control, and adaptive immune responses should be specific to the pathogen presented. A hallmark of the adaptive immune system is clonal expansion of lymphocytes. Recent evidence has indicated that B cells play a critical role in diabetes and its complications; high rates of B-cell depletion delay progression of diabetes-related pathology in non-obese diabetic mice and in new-onset patients.18 B-cell receptor (BCR) specificity to islet autoantigens also contributes to islet-antigen-reactive T-cell function in antigen presentation to diabetogenic CD4+ T cells of Type 1 diabetes.18,19 T cells also play a critical role in diabetes. Experiments have suggested a pathological role for an increase in CD4+ T cells in obesity and insulin resistance; activated CD4+ T cells are increased in visceral adipose tissue of obese mice.20 It has also been shown that obesity induces MHC Class II (MHCII) expression in adipocytes and thus activates CD4+ T cells to initiate inflammation in adipose tissue.21 CD4+ T cells can be further divided into pro-inflammatory Th1 and Th17 cells, as well as anti-inflammatory Th2 and Foxp3+ regulatory T cells (Tregs), based on their functionalities and levels of cytokine production. Th1 cells produce interferon-α (IFN-α), IL-2 and tumour necrosis factor β (TNF-β) to trigger cell-mediated immunity and phagocyte-dependent inflammation.22,23 Th1 cells secrete IFN-γ and enhance pro-inflammatory functions by inducing the release of IL-1 and IL-6. In contrast, Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 to regulate antibody responses.23,24 Collectively, these findings highlight that both innate and acquired immunity play a key functional role in regulating inflammatory processes underlying chronic hyperglycaemia in diabetes, as well as long-term diabetes-related health problems.

Immune cell populations in the heart

Healthy adult mouse heart contains all the major leucocyte classes, including mononuclear phagocytes, neutrophils, dendritic cells (DCs), macrophages, mast cells and eosinophils. Resident macrophages form an immune network that is interspersed with other immune cells throughout the healthy heart and lodged between cardiomyocytes. Macrophages are a type of white blood cell and are classified by their expression of MHCII molecules, CC-chemokine receptor 2 (CCR2) and lymphocyte antigen 6C (Ly6C). CCR2— macrophages are grouped into high and low MHCII subsets, whereas CCR2+ macrophages, which express MHCII, are a minor population. Ly6C+ macrophages are an even smaller population and are the only macrophage subset that expresses Ly6C. T-cell immunoglobulin and mucin domain containing 4 (Tim-4) has emerged as a key marker of resident macrophages in various tissues. In cardiac muscle tissue, Tim-4+ resident cardiac macrophages, which are lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE1) + MHCII low CCR2—, maintain self-renewal despite low input of blood monocytes, and play a non-redundant, cardioprotective role by limiting adverse remodelling.29–31 Resident cardiac DCs represent an extremely small population that comprises less than 1% of all cardiac leucocytes. Two major subsets of DCs are CD103+ CD11b— and CD103 — CD11b+ subsets, which express zinc finger and BTB domain-containing protein 46 (ZBTB46).32 Numerous studies have shown that leucocytes and their subsets, such as neutrophils, monocytes and lymphocytes, are involved in inflammation, which plays an important role in both the initiation and progression of cardiovascular diseases.33

Immune activation in DCM

Abnormal chemical reactions in hyperglycaemia alter normal metabolic processes in diabetes. This is a key process in subcellular inflammation in the early to mid-stages of diabetes, which can lead to heart dysfunction, with patients clinically exhibiting symptoms of myocardial fibrosis, diastolic and systolic dysfunction and clinical heart failure.3 The failing heart contains an increased number of macrophages that expand by both local proliferation of both resident and recruited monocyte-derived macrophages.25 Cardiac macrophages affect other non-myocyte cells including inflammatory cells, vascular cells and fibroblasts and lead to further heart dysfunction. Cardiac macrophages also secrete an extensive array of inflammatory cytokines, chemokines,
growth factors and matrix metalloproteinases (MMPs) to regulate inflammation that directly or indirectly alter the cardiac extracellular matrix (ECM) network. In local immune responses, macrophages receive assistance from other immune cells, such as Toll-like receptor (TLR)-proficient mast cells. TLR activation also induces the production of TNF-α from cardiac macrophages that cause ECM deposition, where transforming growth factor β (TGF-β) is frequently present during hypertrophy in the heart. Inflammatory signals induce release of IL-6, IL-1, IL-10 and IL-18 by macrophages and exacerbate cardiac dysfunction as well as fibrosis in infarcted and non-infarcted hearts; among these signals, IL-18 precipitates adverse cardiac remodelling by reducing capillary density in ischaemic heart tissues. In addition, the role of T cells is clearly documented in tissue fibrosis in cardiac injury. Left ventricular function is protected by T-cell depletion, and Th and Treg subsets significantly participate in inflammation, insulin resistance and vascular alterations in diabetes mellitus. For example, multiple studies have shown that Th1, Th2, Th17 and Th22 cells exhibit many significant signs of pro-inflammatory phenotypes upon the onset of coronary artery disease, which has been reported in DCM patients.

Chemokines are small molecules originating from one ancestral gene, C-X-C motif chemokine ligand 10 (CXCL10), which is secreted by leucocytes and some types of tissue cells under inflammatory stimuli, including human endothelial cells, fibroblasts and cardiomyocytes. CXCL10 increases the migration of inflammatory cells through C-X-C chemokine receptor 3 (CXCR3), which is mainly expressed by T cells, natural killer (NK) cells and monocytes. These data suggest a pivotal role of the CXCL10–CXCR3 axis in early Th1-driven responses, as well as multifaceted functions of CXCL10 in several cardiovascular diseases, which has been previously shown. The discussion above suggests that immune-related molecules may contribute to communication among myocytes, fibroblasts and immune cells in DCM and elucidation of such mechanisms may aid in the development of therapeutic targets for ameliorating diabetic complications. The detailed mechanisms of immune responses in DCM are summarized in Figures 1 and 2C.

RyR1 and RyR2 in the heart

RyRs are a family of Ca²⁺ release channels found on endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR) membranes; they mediate Ca²⁺ release and excitation–contraction (E-C) coupling in both cardiac and skeletal muscles. Three different isoforms of RyRs have been found in mammalian organisms: RyR1, RyR2 and RyR3. RyR1 is expressed in skeletal muscle and smooth muscle, as well as at low levels in cardiac muscle. RyR2 is expressed in cardiac muscle, whereas RyR3 is expressed in the brain. Cryo-electron microscopy (cryo-EM) reconstructions have shown that RyRs have an overall mushroom shape, with the stalk crossing the ER/SR membrane and the large cap being located entirely in the cytosol; the closed-pore and open-pore structures of both RyR1s and RyR2s have been determined to have a resolution of 3.6–6 Å. Structural comparison of open- and closed-pore RyRs has revealed a small armadillo intradomain rearrangement of the

---

**Figure 1** Schematic diagram of the major pathways involved in a model of RCS and AGE that affect Ca²⁺ dynamics and immune responses in fibroblasts in diabetes. RCS and AGES induce release of important immune factors from many different immune cell types, including factors such as TNF-α, interleukin and IFN-γ. In diabetic heart tissue, Ca²⁺ alterations may further contribute to inflammatory responses. Activated immune cells, cytokines and fibroblasts then promote pro-hypertrophic and pro-fibrotic signalling, which induces cardiac hypertrophy and triggers cardiac fibrosis and remodelling. The red arrow denotes an increase in function or concentration. RCS, reactive carbonyl species; AGES, advanced glycation end products; ROS, reactive oxygen species; Cav1.2, L-type Ca²⁺ channels; TNF-α, tumour necrosis factor alpha; TLR9, Toll-like receptor 9; IFN-γ, interferon gamma; IL, interleukin; TFG-β, transforming growth factor beta.
cytoplasmic domains, which are modulated directly or indirectly by L-type Ca\textsuperscript{2+} channels (Ca1.1/1.2), various ions (Ca\textsuperscript{2+}, Mg\textsuperscript{2+}) and protein kinase A (PKA) and have been shown to fine-tune intracellular Ca\textsuperscript{2+} homeostasis.\textsuperscript{11,48} Physiologically, Ca\textsuperscript{2+} entry through L-type Ca\textsuperscript{2+} channels (ICa, L) triggers SR Ca\textsuperscript{2+} release through RyR2 at the junction of the SR. During each heartbeat, these RyR clusters are activated by a relatively small Ca\textsuperscript{2+} influx via L-type Ca channels and provides the trigger to induce Ca\textsuperscript{2+} release from the SR, resulting in cardiac muscle contraction.\textsuperscript{49} RyR2 channels contain several phosphorylation sites. In DCM, PKA and Ca\textsuperscript{2+}/calmodulin-independent protein kinase II (CaMKII) mediate RyR2 phosphorylation and control RyR2 channel activity by RCS and ROS.\textsuperscript{7,50,51} In general, low cytosolic diastolic Ca\textsuperscript{2+} concentrations (<10 μM) increase the open probability (Po) of RyR2 channels. Po is maximal at a Ca\textsuperscript{2+} concentration of approximately 10 μM, and elevating Ca\textsuperscript{2+} concentrations beyond this point (1 mM) leads to a reduction in Po.\textsuperscript{51,52} Western blot analysis of subcellular fractions indicate that in the heart, RyR2 is localized in the SR, whereas RyR1 is localized in mitochondria (mRyR1), suggesting that mRyR1 becomes activated as soon as Ca\textsuperscript{2+} is released from the SR and is maximally activated at a rise in [Ca\textsuperscript{2+}]i. Further increases in the local Ca\textsuperscript{2+} concentration lead to inactivation of mRyR1 to prevent mitochondrial Ca\textsuperscript{2+} overload and opening of permeability transition pores.\textsuperscript{10} RyR1 may be related to immune response in heart failure and DCM.\textsuperscript{53} SR/ER Ca\textsuperscript{2+} ATPase 2a (SERCA2a) is the major isoform of SERCA expressed in cardiomyocytes and plays a crucial role in the regulation of contraction and relaxation during cardiac contractility. SERCA2a transports cytoplasmic Ca\textsuperscript{2+} into the SR. Ca\textsuperscript{2+} stored within the SR is released with each action potential to induce contraction, and muscle contraction is terminated when this Ca\textsuperscript{2+} is transported back into the SR.\textsuperscript{54,55}

RyR in DCM

During the past decade, numerous studies have suggested that increased RyR2 expression is involved in the
pathogenesis of cardiac diastolic dysfunction, systolic dysfunction, heart failure and arrhythmias. However, the role of RyR2 in DCM remains disputed. Hyperglycaemia alters normal metabolic biochemical pathways, resulting in production of RCS and AGEs that accumulate on select basic residues. Mutations of these residues have a physiochemical impact on carbonyl/oxidative stress via RyR channels, with enhanced or reduced cytoplasmic Ca\textsuperscript{2+} responsiveness. Multiple studies have shown that methylglyoxal (one kind of RCS) increases and then decreases the RyR2 Po in experimental models of Type 1 diabetes.\textsuperscript{11,48,57} Diabetes mellitus impairs mitochondrial Ca\textsuperscript{2+} handling in the diabetic heart.\textsuperscript{10,58} Pathological levels of RyR2 phosphorylation lead to heart failure and DCM. Numerous human cardiac tissue studies show that RyR2 phosphorylation and/or mutations can cause deadly ventricular arrhythmias and atrial fibrillation, sinoatrial node and atrioventricular node dysfunction, atrial fibrillation, atrial standstill, dilated cardiomyopathy, heart failure and sudden cardiac death.\textsuperscript{59–61} Diabetic complications are accompanied by increased oxidative stress resulting from the formation of ROS, including superoxide anions, hydrogen peroxide and hydroxyl radicals. These compounds are capable of reacting with reactive cysteines, which cause RyR2 dysfunction. Sulfhydril oxidation by various oxidizing agents has been shown to increase RyR2 Po.\textsuperscript{6,62,63} In addition, reduced activity and expression of SERCA2 protein have been described in heart failure and DCM, resulting in altered Ca\textsuperscript{2+} handling and cardiac contractility.\textsuperscript{55,56} These studies suggest that the dysfunction of RyR may lead to the pathology of DCM. The detailed mechanisms of immune responses in DCM are summarized in Figure 2A,B.

**RyR and immune responses in fibroblasts associated with DCM**

Studies by Zak et al. and Nag et al. have confirmed that the adult rat heart consists of 30% myocytes and 70% non-myocytes.\textsuperscript{54,65} Cardiac fibroblasts respond to a wide range of different stimuli during cardiac development and disease, including abnormal glucose metabolism in diabetes mellitus, as well as changes in chemical and mechanical signals.\textsuperscript{38} Various studies have shown that stimulation of fibroblasts could lead to a marked upregulation of cardiac ECM components, including proteins and polysaccharides secreted by cardiac cell types, ECM-specific receptors and expression of various cytokines and growth factors.\textsuperscript{66} Cardiac fibroblasts are also the main source of the pro-inflammatory cytokine IL-1\textbeta in the heart following injury.\textsuperscript{67} A number of studies have found a close connection between plasma TNF-\alpha levels and the progression of left ventricular remodelling and heart failure,\textsuperscript{68} and animal studies have demonstrated that infusion of TNF-\alpha results in cardiac dysfunction and heart failure.\textsuperscript{57,69,70} It has been shown that TNF-\alpha increases expression levels of IL-1\textbeta and IL-6 in cardiac fibroblasts in vitro. TGF-\beta is another cytokine that is produced by many immune and non-immune cells. TGF-\beta signalling is typically upregulated during heart failure and interacts with its cell surface receptors, with cardiac fibroblasts being the primary producers; thus, the role of TGF-\beta is involved cellular proliferation, cellular differentiation, migration, apoptosis and ECM production to form myofibroblast differentiation.\textsuperscript{66,72} Taken together, these data suggest that immune-related molecules are a key factor in cardiac structure and function in DCM and Ca\textsuperscript{2+} signalling in cardiomyocytes also activates myofibroblasts. In human cardiac myofibroblasts, the expression of Cav1.2 has been detected at the RNA level in human cardiac fibroblasts and ventricular myocytes.\textsuperscript{73,74} Influx of Ca\textsuperscript{2+} through Cav1.2 initiates a much larger Ca\textsuperscript{2+} release from the SR through RyR2 via CICR; the process contributes to the electrical properties of cardiomyocytes. Unlike cardiac myocytes, whose electrical properties, mechanisms of Ca\textsuperscript{2+} signalling and RyRs function in cardiac fibroblasts and myofibroblasts are unclear. For example, RyR1 signalling does not arise from human cardiac fibroblasts; additionally, Ca\textsuperscript{2+} oscillations observed in cultured human cardiac fibroblasts are not influenced by ryanodine or caffeine\textsuperscript{74}; however, functional Cav1.2 currents cannot be obtained via patch-clamp recordings.\textsuperscript{73,75} These results indicate that RyRs and Cav1.2 may indirectly be involved in Ca\textsuperscript{2+} signalling and electrophysiological conditions. Multiple immune cytokines and interleukins, such as TNF-\alpha, IL-1\textbeta and IL-6, have similar effects on intracellular Ca\textsuperscript{2+} handling via modification of RyRs and Cav1.2, thereby influencing fibrosis formation.\textsuperscript{75} The discussion above suggests a number of scenarios and indicate that immune-related molecules, RyRs and Ca\textsuperscript{2+} signalling may be linked to myocyte–fibroblast communication in DCM and may also be functionally relevant to electrical coupling in cardiac myocytes, fibroblasts and immune cells. Figure 1J shows the detailed mechanisms of immune responses and Ca\textsuperscript{2+} signalling in DCM.

**Relevance of mechanisms between RyRs and immune-related molecules in DCM**

As discussed above, the pathophysiology of DCM and heart failure consists of dysfunction of cardiomyocytes, fibroblasts and immune cells. Leaky RyR2 channels contribute to defective cardiac E-C coupling and abnormal properties in fibroblasts that modify the output of the ECM, resulting in abnormal immune responses. TGF-\beta is an important mediator in the differentiation of cardiac fibroblasts to myofibroblast and has been shown to have direct effects on cardiomyocyte function; there is also evidence for the involvement of IL-6 in the communication processes.\textsuperscript{76–78} Evidence for their direct
and indirect effects on communications between cardiac fibroblasts and cardiomyocytes remains unclear. RyRs and immune-related molecules may contribute to mechanisms of cardiomyocyte–fibroblast communication. Studies have shown that inflammatory cytokines impact myocardial function and increase diastolic Ca²⁺ release, which may contribute to arrhythmias. This may, in turn, also induce structural alterations such as myocarditis.⁷⁹ TNF-α and IL-1β increase Ca²⁺ leakage from the SR, which contributes to depressed systolic Ca²⁺ transients, resulting in the cardiac contractile function in arrhythmia in rat ventricular myocytes.⁵⁷,⁸⁰ One possible explanation by which immune-related molecules, such as TNF-α and IL-1β, increase mimic detrimental effects on triggered SR Ca²⁺ release from the SR is that RyR2 clusters involved in the calcium sparks and calcium transients may be refractory to triggered CICR.⁸⁰ It has been shown that RyR1 is expressed in lymphocytes, DCs and macrophages.¹⁸,⁵³,⁸¹,⁸² Studies on the role of RyR1 have suggested that activation of B lymphocytes is coupled to inflammatory cytokine release⁸³ and leads to enhanced DCs, release of pro-inflammatory cytokines and enhanced priming of T cells.⁸¹ Kho et al.⁵⁵ have shown that B lymphocytes exhibit leaky RyR1 channels, leading to reduced ER Ca²⁺ stores and Ca²⁺ dysregulation in chronic heart failure. Expression of RyR1/RyR2 mRNA has additionally been reported in human T cells, and RyR1/RyR2 protein immunoreactivity using primary antibody was seen in activated but not in resting T cells. The RyR agonist caffeine evokes [Ca²⁺]i transients recorded from activated T cells but not in resting T cells. These data indicate that RyR expression is functionally upregulated in activated T cells, suggesting that RyRs are an important regulator of Ca²⁺ signalling and Ca²⁺-dependent functions in immune cells for modulating immune responses in humans.⁸¹–⁸⁷ Several reports of pharmacological inhibition of RyRs by ryanodine or dantrolene demonstrate effects on major functions of human T cells such as Ca²⁺ release via RyRs, which is not a direct result of TCR activation but instead depends on RyRs activation by Ca²⁺ originating from store-operated Ca²⁺ entry; inhibition of RyRs reduces T-cell proliferation and IL-2 production.⁸⁵,⁸⁶ Figure 3 shows how RyRs affect T-cell function during T-cell activation. These studies collectively indicate that alterations in Ca²⁺ signalling and abnormal immune responses may represent another source of cardiomyopathy. Evidence suggests that

---

**Figure 3** RCS and AGEs affect organelar Ca²⁺ channels and modulators of Ca²⁺ signalling during T-cell activation. The role of IP3 in initiating and sustaining T-cell Ca²⁺ signalling is well established. NAADP and cADPR are proposed to synergize with IP3 during T-cell Ca²⁺ signalling; NAADP activates RyR1 and causes ER Ca²⁺ release, which synergizes with IP3 to cause further Ca²⁺ release via IP3 receptors (IP3Rs). In addition, activation of RyR2 by cADPR serves to sustain Ca²⁺ signalling for T-cell function. Ca²⁺ entry through ORAI channels may activate RyR isofroms to maintain store depletion and SOCE. Mitochondrial Ca²⁺ uptake through the mitochondrial MCU at the vicinity of ORAI channels maintains CRAC channel activity by relieving its CDI. Expression of CaV1.2 and CaV1.1 at the plasma membrane may affect TCR-activated Ca²⁺ entry and nuclear factor for activated T-cell (NFAT) activity. One intriguing hypothesis in T cells is the existence of a conformational coupling between CaV1.1, CaV1.2 and RyRs. RCS and AGEs affect RyR function and alter Ca²⁺ signalling in T cells. This intriguing possibility in T cells may further contribute to cross-communication between fibroblasts and cardiomyocytes. The red arrow denotes an increase in function or concentration. CRAC, Ca²⁺ release-activated Ca²⁺; NAADP, nicotinic acid adenine dinucleotide phosphate; cADPR, cyclic ADP ribose; ER, endoplasmic reticulum; IP3, inositol-1,4,5-trisphosphate; IP3R, IP3 receptor; SOCE, store operated Ca²⁺ entry; MCU, Ca²⁺ uniporter; CDI, Ca²⁺-dependent inhibition; TCR, T-cell receptor 90.
interactions among RyR1, RyR2, Ca^{2+} signalling and immune-related molecules may directly or indirectly be affected in diabetic hearts during some pathophysiological stages in DCM. Further elucidation of the relationship between RyRs and immune-related molecules will likely improve treatments for mitigating diabetic complications.

**Conclusion and future directions**

The heart contains cardiomyocytes, cardiac fibroblasts and many kinds of immune cells. Initial studies mainly focused on RyR2 in cardiomyocytes because RyR2 directly reflects the contractile function of the heart. RyR1 is also expressed in cardiac tissue but at low levels. RyR1 and RyR2 collectively control cytosolic Ca^{2+} concentrations to maintain cardiomyocytic function. Physiological functions of cardiac fibroblasts are capable of eliciting an immune response to protect the function of cardiomyocytes. Contributions from immune cells, such as T lymphocytes and monocyte/macrophage-lineage cells, have also been reported in cardiac tissue. The past few decades have generated a growing recognition that the immune system provides an important contribution to cardiac development, composition and function. Evidence suggests that interactions among RyRs, Ca^{2+} signalling and the immune system may be directly or indirectly affected in diabetic hearts. Elucidation of RyRs and immune-related molecules has significantly contributed to our understanding of intercellular communication among cardiomyocytes, cardiac fibroblasts and immune cells (Figure 4). Our understanding of the complex communication between immune cells and RyRs in cardiac tissue remains incomplete. Future studies should focus on determining the components that intervene between individual immunity molecules and RyR function in diabetes, which will be crucial for obtaining invaluable insights into the design of therapeutic approaches to prevent and/or treat DCM in humans.

**Acknowledgement**

This work was supported by the National Natural Science Foundation of China grant numbers 81873267 and 81173451.

**Conflict of interest**

The authors declare that they have no competing interests.
References

1. Holscher ME, Bode C, Bugger H. Diabetic cardiomyopathy: does the type of diabetes matter? Int J Mol Sci 2016; 17: 2136.
2. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinemia in diabetic cardiomyopathy. Nat Rev Endocrinol 2016; 12: 144–153.
3. Kenny HC, Abel E. Heart failure in type 2 diabetes mellitus impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circ Res 2019; 124: 121–141.
4. Bellier J, Nokin MJ, Larde E, Karopyan P, Peulen O, Castronovo V, Bellahcene A. Methyglyoxal, a potent inducer of AGEs, connects between diabetes and cancer. Diabetes Res Clin Pract 2019; 148: 200–211.
5. Mano J, Kanameda S, Kuramitsu R, Matsuura N, Yamauchi Y. Detoxification of reactive carbonyl species by glutathione transferase tau isoforms. Front Plant Sci 2019; 10: 487.
6. Nikolaienko R, Bovo E, Zima AV. Redox dependent modifications of ryanoide receptor: basic mechanisms and implications in heart diseases. Front Physiol 2018; 9: 1775.
7. Eisner DA, Caldwell JL, Kistamas K, Trafton AW. Calcium and excitation-contraction coupling in the heart. Circ Res 2017; 121: 181–195.
8. Mayourian J, Ceholski DK, Gonzalez DM, Cashman TJ, Sahoo S, Hajar RJ, Costa KD. Physiologic, pathologic, and therapeutic paracrine modulation of cardiac excitation-contraction coupling. Circ Res 2018; 122: 167–183.
9. Lascano E, Negroni J, Vila Petroff M, Mattiazzi A. Impact of Ryr2 potentiation on myocardial function. Am J Physiol Heart Circ Physiol 2017; 312: H1105–H1109.
10. Beutner G, Sharma VK, Lin L, Ryu S-Y, Dirksen RT, Sheu S-S. Type 1 ryanodine receptor: basic mechanisms and implications of ryanodine receptor function in diabetes mellitus. Mol Pharmacol 2012; 82: 383–399.
11. Shao CH, Tian C, Ouyang S, Moore CJ, Alomar F, Nemet I, D’Souza A, Nagai R, Kutty S, Rozanski GJ, Ramanadham S, Singh J, Bidasee KR. Carbylation induces heterogeneity in cardiac ryanodine receptor function in diabetes mellitus. Mol Pharmacol 2012; 82: 383–399.
12. Tian CJ, Zhen Z. Reactive carbonyl species: diabetic complication in the heart and lungs. Trends Endocrinol Metab 2019; 30: 546–556.
13. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail 2017; 19: 1379–1389.
14. Filardi T, Ghinassi B, Di Baldassarre A, Tanzilli G, Morano S, Lenzi A, Basili S, Crescioli C. Cardiomyopathy associated with diabetes: the central role of the cardiomyocyte. Int J Mol Sci 2019; 20: 3299.
15. Jacobsen LM, Newby BN, Perry DJ, Posgay AI, Haller MJ, Brusko TM. Immune mechanisms and pathways targeted in type 1 diabetes. Curr Diab Rep 2018; 18: 90.
16. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophisiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J 2016; 92: 63–69.
17. Dalmas E. Innate immune priming of insulin secretion. Curr Opin Immunol 2019; 56: 44–49.
18. Hinman RM, Cambier JC. Role of B lymphocytes in the pathogenesis of type 1 diabetes. Curr Diab Rep 2014; 14: 543.
19. Ahmed R, Omidian Z, Giwa A, Cornwell B, Majety N, Bell DR, Lee S, Donner T, Hamad ARA. A public BCR present in a unique dual-receptor-expressing lymphocyte from type 1 diabetes patients encodes a potent T cell autoantigen. Cell 2019; 177: 1583–1599.
20. Newton R, Priyadarshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol 2016; 17: 618–625.
21. Cho KW, Morris DL, Proposto JD, Geletka L, Zamarron B, Martinez-Crescioli C, Meyer KA, Singer K, O’Rourke RW, Lumeng CN. An MHC II-dependent activation loop between adipose tissue macrophages and CD4+ T cells controls obesity-induced inflammation. Cell Rep 2014; 9: 605–617.
22. Walker LS, von Herrath M. CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol 2016; 183: 16–29.
23. Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol 2019; 19: 734–746.
24. Narsale A, Moya R, Davies JD. Human CD4+ CD25+ CD127hi cells and the Th1/Th2 phenotype. Clin Immunol 2018; 188: 103–112.
25. Honold I, Nahrendorf M. Resident and monocye-derived macrophages in cardiovascular disease. Circ Res 2018; 122: 113–127.
26. Swirski FK, Robbins CS, Nahrendorf M. Development and Function of Arterial and Cardiac Macrophages. Trends Immunol 2016; 37: 32–40.
27. Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol 2018; 18: 733–744.
28. Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao H, Weinheimer C, Kovacs A, Epelman S, Artymov M, Kreisel D, Lavine KJ. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res 2019; 124: 263–278.
29. Dick SA, Macklin JA, Nejat S, Clemente-Casares X, Momen A, Kantores C, Hosseinmazar S, Barbui I, Chen J, Albagiﬁ MG, Besla R, Wong A, Aronoff L, Zaman R, Lavine KJ, Razani B, Ginhoux F, Husain M, Cybulsky MJ, Robins CS, Epelman S. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat Immunol 2019; 20: 29–39.
30. Liu W, Xu L, Liang X, Liu X, Zhao Y, Ma C, Gao L. Tim-4 in health and disease: friend or foe? Front Immunol 2020; 11: 537.
31. Tucker NR, Chaffin M, Fleming SJ, Hall AW, Parsons VA, Bedi KC, Akkad AD, Herndon CN, Ardini A, Papangeli I, Roselli C, Aguet F, Choi SH, Ardlie KG, Babadi M, Margulies KB, Stegmann CM, Ellinor PT. Transcriptional and cellular diversity of the human heart. Circulation 2020; 142: 466–482.
32. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontology and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31: 563–604.
33. Bajpai A, Tilley DG. The role of leukocytes in diabetic cardiomyopathy. Front Physiol 2018; 9: 1547.
34. Frieler RA, Mortensen RM. Immune cell and other non-cardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 2015; 131: 1019–1030.
35. Zaharieva E, Velikova T, Tsakov A, Kamenov Z. Reduced soluble toll-like receptors 2 in type 2 diabetes. Arch Physiol Biochem; 124: 326–329.
36. Shintani Y, Drexler HCA, Kioka H, Terracciano CMN, Coppen SR, Imamura H, Ako M, Nakai J, Wheeler AP, Higo S, Nakayama H, Takashima S, Yashiro K, Suzuki K. Toll-like receptor 9 protects non-immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2. EMBO Rep 2014; 15: 438–445.
37. Adamo L, Rocha-Resende C, Prabhudda S, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020; 17: 269–285.
failing heart. JACC Basic Transl Sci 2019; 4: 449–467.

39. Altara R, Mallat Z, Booz GW, Zouein FA. The CXCL10/CXCR3 axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart. J Immunol Res 2016; 2016: 4396368.

40. Noels H, Weber C, Koenen RR. Chemokines as therapeutic targets in cardiovascular disease. Arterioscler Thromb Vasc Biol 2019; 39: 583–592.

41. Meissner G. The structural basis of ryanodine receptor ion channel function. J Gen Physiol 2017; 149: 1065–1089.

42. Gong D, Chi X, Wei J, Zhou G, Huang G, Zhang L, Wang R, Lei J, Chen SRW, Yan N. Modulation of cardiac ryanodine receptor 2 by calmodulin. Nature 2019; 572: 347–351.

43. Peng W, Shen H, Wu J, Guo W, Pan X, Wang R, Chen SR, Yan N. Structural basis for the gating mechanism of the type 2 ryanodine receptor RyR2. Science 2016; 354: aah5324.

44. Cui W, Wu J, Li Z, Xie T, Peng W, Yin C, Li X, Scheres SHW, Shi Y, Yan N. Structure of the rabbit ryanodine receptor RyR1 at near-atomic resolution. Nature 2015; 517: 50–55.

45. Chi X, Gong D, Ren K, Zhou G, Huang G, Lei J, Zhou Q, Yan N. Molecular basis for agonist regulation of the type 2 ryanodine receptor channel gating by key modulators. Proc Natl Acad Sci 2019; 116: 25575–25582.

46. Georges A, Clarke OB, Zalk R, Yuan Q, Condon KJ, Grassucci RA, Hendrickson WA, Marks AR, Frank J. Structural basis for gating and activation of RyR1. Cell 2016; 167: 145–157.

47. Bai XC, Yan Z, Wu J, Li Z, Yan N. The central domain of RyR1 is the transducer for cAMP-dependent protein kinase (PKA) signal transduction. J Gen Physiol 2014; 144: 263–271.

48. Kushnir A, Santulli G, Reiken SR, Coromilas E, Godfrey SJ, Brunjes DL, Colombo PC, Yuzeipolskaya M, Sokol SI, Kitsis RN, Marks AR. Ryanodine receptor calcium leak in circulating B-lymphocytes as a biomarker in heart failure. Circulation 2018; 138: 1144–1154.

49. Chen X, Zhang X, Gross S, Houser SR, Soboloff J. Acatyelation of SERCA2a, another target for heart failure treatment? Circ Res 2019; 124: 1285–1287.

50. Laver DR, Roden LD, Ahern GP, Eager KR, Junankar PR, Dulhunty AF. Cardiac RYR2 S2808 or RyR2-S2814. J Mol Cell Cardiol 2019; 130: 96–106.

51. Wang R, Chen SR, Yan N. Structural basis for gating and activation of RyR1. Cell 2016; 167: 159–169.

52. Walweel K, Li J, Molenaar P, Imtiaj MS, Quail A, dos Remedios CG, Beard NA, Dulhunty AF, van Helden DF, Laver DR. Differences in the regulation of RyR2 from human, sheep, and rat by Ca2+ and Mg2+ in the cytoplasm and in the lumen of the sarcoplasmic reticulum. J Gen Physiol 2014; 144: 263–271.

53. Sanchez G, Pedrozo Z, Domenech RJ, Hidalgo C, Donoso P. Tachycardia increases NADPH oxidase activity and RyR2 S-glutathionylation in ventricular muscle. J Mol Cell Cardiol 2005; 39: 982–991.

54. Nag A. Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. Cytobios 1980; 28: 41–61.

55. Zak R. Development and proliferative capacity of cardiac muscle cells. Circ Res 1974; 32: 17–26.

56. Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res 2019; 125: 117–146.

57. Szekely Y, Arbe Y. A review of interleukin-1 in heart disease: where do we stand today? Cardiol Ther 2018; 7: 24–44.

58. Sun M, Chen M, Dawood F, Zurasawa U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-a mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007; 115: 1398–1407.

59. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 2015; 116: 1254–1268.

60. Schumacher SM, Naga Prasad SV. Tumor necrosis factor-a in heart failure: an updated review. Curr Cardiol Rep 2018; 20: 117.

61. Turner NA, Mughal RS, Warburton P, O’Regan DJ, Ball SG, Porter KE. Mechanism of TNF alpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res 2007; 76: 81–90.

62. Souders CA, Bowers SLK, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009; 105: 1164–1176.

63. Peng J, Armillei MK, Yu AS, Liang BT, Runnels IW, Yue L. Ca2+ signaling in cardiac fibroblasts and fibrosis-associated heart diseases. J Cardiovasc Dev Dis 2019; 6: 34.

64. Chen JB, Tao R, Sun HY, Tse HF, Lau CP, Li GR. Multiple Ca2+ signaling pathways regulate intracellular Ca2+ activity in human cardiac fibroblasts. J Cell Physiol 2010; 222: 268–275.

65. Ding Z, Yuan J, Liang Y, Wu J, Gong H, Ye Y, Jiang G, Yin P, Li Y, Zhang G, Yang C, Guo J, Chen Z, Wang X, Weng L, Zou Y. Ryanodine receptor type 2 plays a role in the development of cardiac fibrosis under mechanical stretch through TGFβ-1. Int J Heart J 2017; 58: 957–961.

66. Pellman J, Zhang J, Sheikh F. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: mechanisms and model systems. J Mol Cell Cardiol 2016; 94: 22–31.

67. Cartledge JE, Kane C, Dias P, Tesfom M, Clarke I, Mckee B, Al Ayoubi S, Chester A, Yacoub MH, Camelliti P, Terracciano CM. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res 2015; 105: 260–270.

68. Hall C, Gehmlich K, Denning C, Pavlovic D. Complex relationship between cardiac fibroblasts and cardiomyocytes in health and disease. J Am Heart Assoc 2021; 10: e019338.
79. Lazzerini PE, Capecchi PL, El-Sherif N, Laghi-Pasini F, Boutjdir M. Emerging arrhythmic risk of autoimmune and inflammatory cardiac channelopathies. J Am Heart Assoc 2018; 7: e010595.

80. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrisona SM. TNF-α and IL-1β increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 2010; 47: 378–386.

81. Bracci L, Vukcevic M, Spagnoli G, Ducreux S, Zorzato F, Treves S. Ca2+ signaling through ryanodine receptor 1 enhances maturation and activation of human dendritic cells. J Cell Sci 2007; 120: 2232–2240.

82. Uemura Y, Liu TY, Narita Y, Suzuki M, Ohshima S, Mizukami S, Ichihara Y, Kikuchi H, Matsushita S. Identification of functional type 1 ryanodine receptors in human dendritic cells. Biochem Biophys Res Commun 2007; 362: 510–515.

83. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S. B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001; 276: 48077–48082.

84. Strassheim D, Dempsey EC, Gerasimovskaya E, Stenmark K, Karoor V. Role of inflammatory cell subtypes in heart failure. J Immunol Res 2019; 2019: 2164017.

85. Thakur P, Dadsetan S, Pomina AF. Bidirectional coupling between ryanodine receptors and Ca2+ release-activated Ca2+ (CRAC) channel machinery sustains store-operated Ca2+ entry in human T lymphocytes. J Biol Chem 2012; 287: 37233–37244.

86. Trebak M, Kinet JP. Calcium signalling in T cells. Nat Rev Immunol 2019; 19: 154–169.

87. Diercks BP, Werner R, Weidemüller P, Czarniak F, Hernandez I, Lehmann C, Rosche A, Kruger A, Kaufmann U, Vaeth M, Failla AV, Zobiak B, Kandil FI, Schetelig D, Ruthenbeck A, Meier C, Lodygin D, Flugel A, Ren D, Wolf IMA, Feske S, Guse AH. ORAI1, STIM1/2, and RYR1 shape subsecond Ca 2+ microdomains upon T cell activation. Sci Signal 2018; 11: eaat0358.